Liminatus Pharma, Inc. Class A Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LIMN research report →
Price Chart
About the company
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
- CEO
- Chris Kim
- IPO
- 2025
- Employees
- 1
- HQ
- Cerritos, CA, US
Get TickerSpark's AI analysis on LIMN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.56M
- P/E
- -0.25
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 18.13
- EV/EBITDA
- -0.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 443.60%
- ROIC
- -225.12%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-2,967,812
- Net Income
- $-10,206,517-251.4%
- EPS
- $-0.43-7.5%
- OCF Growth
- -220.7%
- FCF Growth
- -221.2%
- 52W High
- $4.06
- 52W Low
- $0.10
- 50D MA
- $0.12
- 200D MA
- $0.40
- Beta
- 0.74
- RSI (14)
- 47
- Avg Volume
- 40.80M
No earnings-call transcripts are available for LIMN yet.
- Free Float
- 35.3%
- Shares Outstanding
- 67.16M
- Float Shares
- 23.68M
of shares held by institutions
12 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 73.42K | 0 |
Held by 4 ETFs
Biggest fund positions in LIMN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 2, 26 | Valetudo Therapeutics LLC | other | 3,448,926 |
| Jun 24, 26 | Valetudo Therapeutics LLC | other | 4,373,603 |
| Jun 24, 26 | Ewon Comfortech Co., Ltd. | other | 0 |
| Apr 30, 25 | Iris Acquisition Holdings LLC | other | 0 |
| Jul 10, 25 | Lemons II Philip Wayne | other | 0 |
| Jul 10, 25 | Baek Richard JaiHwan | other | 0 |
| Apr 30, 25 | KH Feelux Co., Ltd | other | 0 |
| Apr 30, 25 | Valetudo Therapeutics LLC | other | 0 |
| Apr 30, 25 | Lee Eun Sook | other | 0 |
| Apr 30, 25 | Baek Ji Yeon | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LIMN coverage
Recent articles, reports, and earnings notes.
No research on LIMN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LIMN report →Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
globenewswire.com · Aug 18
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
globenewswire.com · Aug 13
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
globenewswire.com · Jun 30
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
globenewswire.com · Jun 3
Liminatus Pharma Announces Nasdaq Delisting Notification
globenewswire.com · May 21
Liminatus Pharma Announces Nasdaq Delisting Notification
globenewswire.com · May 21
Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session
feeds.benzinga.com · May 21
Athira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN) Head to Head Analysis
defenseworld.net · Mar 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.